The Lymphoma Hub was pleased to speak with Gloria Iacoboni, Vall d'Hebron University Hospital, Barcelona, ES. We asked, What are the key findings from the DALY 2-EU trial of zamtocabtagene autoleucel (zamto-cel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL)?&nbsp; This educational resource is independently supported by Miltenyi Biomedicine. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.&nbsp;<hr> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.

The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma and CLL. Our aim is to enhance knowledge in lymphoma and CLL, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management. Hosted on Acast. See acast.com/privacy for more information.